Skip to main content
Notice2022-16499

Policy Regarding N-acetyl-L-cysteine; Guidance for Industry; Availability

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
August 2, 2022

Issuing agencies

Health and Human Services DepartmentFood and Drug Administration

Abstract

The Food and Drug Administration (FDA or we) is announcing the availability of a final guidance for industry entitled "Policy Regarding N-acetyl-L-cysteine." The guidance explains our intent to exercise enforcement discretion with respect to the sale and distribution of certain products that contain N-acetyl-L-cysteine (NAC) and are labeled as dietary supplements. This enforcement discretion policy applies to products that would be lawfully marketed dietary supplements if NAC were not excluded from the definition of "dietary supplement" and that are not otherwise in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Indexed from Federal Register on August 2, 2022.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.